Navigation Links
American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
Date:9/4/2007

DALLAS, Sept. 4 /PRNewswire-USNewswire/ -- A small reduction in blood pressure produced a significant benefit in the largest study ever done on the treatment of patients with type 2 diabetes, presented on Sunday in Vienna at the European Society of Cardiology Congress, and published online in the Lancet the same day.

Stephen MacMahon, Ph.D., M.P., described the results of ADVANCE, a randomized, placebo-controlled study in which 11,140 patients received either placebo or a single pill containing a fixed combination of an ACE inhibitor (perindopril) and a thiazide-like diuretic (indapamide). While the reduction in blood pressure was modest (an average of 5.6/2.2 mm Hg), at 4.3 years the treated group had a relative risk reduction of 14 percent for coronary heart disease events, 18 percent for cardiovascular deaths, 14 percent for deaths of any cause, and 21 percent for developing new or worsening kidney disease.

Daniel W. Jones, M.D., President of the American Heart Association, commented, "We spend both great effort and considerable financial resources in trying to treat diabetes effectively, and here is a simple and inexpensive way to save lives. Just lower the blood pressure!"

MacMahon calculated that one death could be avoided among every 78 patients treated for five years. Because type-2 diabetes is so common worldwide, he added that treatment such as this could prevent as many as 1.5 million deaths, even if given to only half of the world's diabetics.

The benefit for treated patients was seen both in the group who began with blood pressures above 140/90 and those who began at levels below this cut-off. It was also apparent whether or not patients were also on other blood- pressure-lowering drugs, statins, ACE inhibitors, and aspirin.

The American Heart Association points out that the majority of deaths in diabetic patients are due to cardiovascular disease. Dr. Jones added, "Having diabetes alone elevates an individual's risk
'/>"/>

SOURCE American Heart Association
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
7. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
10. Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes
11. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2008)...May 20 /- Omeros Corporatio...ment for the Phase 1 study of,OMS201, the Company,...e,for use during urological surgery. At least 24 ...al of stones with a maximum diameter of 12 mm,loca...be enrolled in the,study., "Advancing another Pha...
(Date:5/20/2008)...rial data for Perforomist(TM) (Formoterol Fumarate...tional ATS Conference --, NAPA, Calif., May 20 /P...ional Conference of the American Thoracic Society ...rforomist(TM) Inhalation Solution,(formoterol fuma...lization,and Spiriva(R) (tiotropium; TIO) is sign...
(Date:5/20/2008)...ented at the 2008 International Conference of the ...ty, TORONTO, May 20 /- For...S.A. today presented results from four clinical,tr...um bromide, an,investigational treatment for chron... four preclinical studies further describing the p...
(Date:5/20/2008)...May 20 /- GlaxoSmithKline and Synta,P...ced positive Phase II,clinical data for elesclomol...rently in development for metastatic melanoma. A r...tic melanoma patients treated with elesclomol,and ...erapy had a,statistically significant improvement ...
Breaking Medicine Technology:Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study 2Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 2Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 3Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 4Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 5Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 6Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 2Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 3Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 4Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 5Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 2Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 3Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 4Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 5Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 6Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 7Blue Cross and Blue Shield of Texas Launches an Integrated Medical Dental Health Program 2995 1Blue Cross and Blue Shield of Texas Launches an Integrated Medical Dental Health Program 2995 2Blue Cross and Blue Shield of Texas Launches an Integrated Medical Dental Health Program 2995 3AACN Concerned That the Presidents FY 2009 Budget Request Will Prolong the Nursing and Nurse Faculty Shortage 10961 1AACN Concerned That the Presidents FY 2009 Budget Request Will Prolong the Nursing and Nurse Faculty Shortage 10961 2AACN Concerned That the Presidents FY 2009 Budget Request Will Prolong the Nursing and Nurse Faculty Shortage 10961 3DURECT to Present at BIO CEO Investor Conference 2008 10959 1Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 1Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 2Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 3Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 4Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 5Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 6Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 7Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 8Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 9Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 10Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 11Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 12Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 13Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 14Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 15Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 16Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 17Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 18Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 19Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 20Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 21Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 22Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 23Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 24Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 25Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 26Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 27Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 28Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31 2007 2993 29
...ignificant additional protection against,infection...rvical,cancer candidate vaccine, PHILADELPHIA, Jun...an interim analysis of a Phase III study show that...candidate vaccine,provides up to 100 percent prot...d by the most common types of human papillomavirus...
...tients treated with VELCADE, cyclophosphamide,and... 28, 2007 /PRNewswire-FirstCall/ -- Millennium,Pha...ion of results,from clinical trials of VELCADE bas... complete response(1) (CR) rates in previously,tre...s were,presented at the prestigious 11th Internati...
Other Medicine Technology:Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 2Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 3Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 4Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 5Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 6Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 7Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 2Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 3Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 4Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 5Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 6
(Date:5/20/2008)...alth care problem all over the world, with 130 mil...nt is expensive and has variable results according... land mark in treatment is the virus clearance at ...onse (ETR), but many of the patients achieving the...us, the goal of treatment is to have persistent vi...
(Date:5/20/2008)...erless prescription use yields practical guides fo...nd policy makers, WASHINGTON, MAY 20 /PRNewswire-...eHI) and the Center for Improving Medication Manag... anticipated report detailing the,impact of electr...,consumers, employers, health plans and policy mak...
(Date:5/20/2008)...APOLIS, May 20 /PRNewswire/ -- On May 25, one brig...Honda, will be racing to win,the Indianapolis 500 ...s --,Eyes on the Road. By emblazoning their car on...tp://www.eyesontheroad.org, IndyCar owners Jay Pe...s driver, IndyCar Series,veteran Tomas Scheckter o...
(Date:5/20/2008)...nhaling long, thin carbon nanotubes may result in,...ewswire-USNewswire/ -- A major study published,tod... carbon nanotubes -- a,poster child for the "nanot...bestos if inhaled in sufficient quantities., The ...types of,nanotubes have the potential to cause mes...
Breaking Medicine News(10 mins):Health News:eHealth Initiative and the Center for Improving Medication Management to Present Report Detailing Both Impact of E-Prescriptions on U.S. Health Care System and Guidelines for Achieving Optimal Results 2Health News:eHealth Initiative and the Center for Improving Medication Management to Present Report Detailing Both Impact of E-Prescriptions on U.S. Health Care System and Guidelines for Achieving Optimal Results 3Health News:Luczo Dragon IndyCar Carries 'Eyes on the Road' Logo to Prevent Blindness to Indy 500 2Health News:Carbon Nanotubes That Look Like Asbestos, Behave Like Asbestos 2Health News:Carbon Nanotubes That Look Like Asbestos, Behave Like Asbestos 3Health News:Carbon Nanotubes That Look Like Asbestos, Behave Like Asbestos 4
... study of Chinese people has linked obesity with a...population . Led by Chi C. Leung at the Tuberculo...examined 42,116 individuals aged 65 years or above... centres for elderly patients in Hong Kong. The r...
...h Sheriff Lee Baca has justified placing Paris Hil...g psychiatric condition as the reason, it seems th...the slammer was quite sure that the socialite was ..., Larry Waldie, who had informed Judge Sauer about...
...NGTON - A U.S. consumer group called for an urgent...fety of aspartame as it can be cancerous, on Mond... to do so despite a new study showing the sweetene...ished by the Italian researchers points to the fac...
...h Minister Jose Gomes Temporao plans to distribute...ew months in office, Brazils new health minister ... offerings. Brazil's government has added "morning...birth control program in hopes of helping poor peo...
Other Medicine News:Health News:Aspartame Probe Call Rejected by FDA 2Health News:Brazil Government New Health Offer 2Health News:Brazil Government New Health Offer 3
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use.
The 8600 Series Tabletop/Portable Digital Pulse Oximeter provides a simple universal tool for patient monitering. From transport applications to continuous monitoring, the 8600 has earned the confide
Halogen-free immersion oil based on ester oil.
Immersion oil composed on polyester polyol, diphenyl cresyl phosphate and tricyclodecane dimethanol.
Medicine Products: